The reason for undertaking the study described in this report is the suggestion that pain is still inadequately managed. The pain management of 3030 patients receiving care from 141 European palliative care centers in 21 European countries was assessed. A single day's snap shot of these patients was created through input from the clinicians. One weakness of this study is the use of clinician reports in rating pain and other symptoms rather than patient ratings. The most solid data captured was, in fact, the opioids used as well as the administered dose.
There was great variation in the use of the different drugs between different countries. It will be interesting to see other investigators assess and discuss the reasons for this and in fact, it may make for interesting dialogue in the Journal. Are these differences related to the different nation's laws, or marketing, or are there factors related to a country's health care system, or the history of palliative care that impact this prescribing? Examples of such a review was seen in the UK, where morphine was used in 38%YO of patients, although historically the 'home of oral morphine'. Diamorphine was solely used in the UK and ( 2005 Edward Arnold (Publishers) Ltd Belgium. Romania had an interesting panel with 25% of patients using dextropropoxyphene, 23% tramadol and 14% codeine; that is almost two-thirds of patients which were prescribed step two drugs. Only 30% used step 3 drugs (morphine: 18%; methadone: 12%). As efforts are made to rewrite the opioid prescribing laws in Romania, the impact on individual prescribing could serve as an important measure for quality improvement.
Equally, the use of individual drugs can be reviewed. It is indeed interesting to see the low penetration of oxycodone into these countries. Synthesized in Germany in 1916, it constitutes <4% of opioid use in the 21 countries. Israel has the highest number of prescriptions followed by Finland, with almost a quarter of the patients using oxycodone. Finland is well known for the work of Kalso et al. with oxycodone,9 and has a parenteral form of the drug available for intravenous administration. The reasons for Israel's high consumption are worthy of exploration. In addition, there is much variation in the prescribing of fentanyl, while representing 13% of all patients. Excluding the low numbers in Luxembourg, Romania was the only country not to use some fentanyl. Rates ranged up to half of the 42 patients in the Netherlands, 40% in Denmark and 41% of patients in Greece. There have been several industry funded studies on fentanyl by Greek investigators, providing one possible reason for its heavy use.10 So, this is a fascinating snapshot of 'a day in the life of European palliative care'. But as with any photo collection, the finished product is very dependent on both sites and subjects chosen. For some countries, the number of subjects and indeed the number of centers were small. The impact of a pattern of prescribing from a heavy recruiter may not be truly reflective of the country. Countries may choose to expand this work within their boundaries to reach a fuller understanding of their own situation. Regardless, this is an important study, which can be used to ensure an improvement in palliative care across Europe. James F Cleary The University of Wisconsin, Wisconsin 10 .1191/0269216305pmlO65ed
